Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Cipla had earlier invested € 15 million in Ethris in 2022
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Subscribe To Our Newsletter & Stay Updated